Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 5/20 | 0.41 |
| ▸ | IKBKB | O14920 | 1/20 | 0.41 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.38 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.38 |
| ▸ | ADRB3 | P13945 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PTAFR | P25105 | 1/20 | 0.37 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8051025 | 0.90 | CYP3A4 (0.47) | NAMPTCYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL504220 | 0.90 | CYP3A4 (0.47) | NAMPTCYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL504466 | 0.90 | CYP3A4 (0.47) | NAMPTCYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL504459 | 0.90 | CYP3A4 (0.47) | NAMPTCYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL504267 | 0.90 | CYP3A4 (0.47) | NAMPTCYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL504458 | 0.90 | CYP3A4 (0.47) | NAMPTCYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL8054318 | 0.90 | CYP3A4 (0.47) | NAMPTCYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL504467 | 0.90 | CYP3A4 (0.47) | NAMPTCYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL8054097 | 0.90 | CYP3A4 (0.47) | NAMPTCYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL504829 | 0.90 | CYP3A4 (0.47) | NAMPTCYP3A4CYP2D6CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7807682-B2 | Pyridyl cyanoguanidine compounds | LEO PHARMA A/S (DK) | 2010-10-05 | — | — | US | claimed |
| EP-1397355-B1 | PYRIDYL CYANOGUANIDINE COMPOUNDS | LEO PHARMA AS (DK) | 2009-09-09 | — | — | EP | claimed |
| US-20080090842-A1 | Novel pyridyl cyanoguanidine compounds | LEO PHARMA A/S (DK) | 2008-04-17 | — | — | US | claimed |
| US-7304066-B2 | Pyridyl cyanoguanidine compounds | LEO PHARMA A/S (DK) | 2007-12-04 | — | — | US | claimed |
| US-7807682-B2 | Pyridyl cyanoguanidine compounds | LEO PHARMA A/S (DK) | 2010-10-05 | — | — | US | disclosed |
| EP-1397355-B1 | PYRIDYL CYANOGUANIDINE COMPOUNDS | LEO PHARMA AS (DK) | 2009-09-09 | — | — | EP | disclosed |
| US-20080090842-A1 | Novel pyridyl cyanoguanidine compounds | LEO PHARMA A/S (DK) | 2008-04-17 | — | — | US | disclosed |
| US-7304066-B2 | Pyridyl cyanoguanidine compounds | LEO PHARMA A/S (DK) | 2007-12-04 | — | — | US | disclosed |
| US-20040220408-A1 | Novel pyridyl cyanoguanidine compounds | LEO PHARMA A/S (DK) | 2004-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220408-A1 | Novel pyridyl cyanoguanidine compounds | DAO, AOC1, SIGMAR1 | NAMPT 2639/4885CYP3A4 814/4885CYP2D6 66/4885 |
| US-20080090842-A1 | Novel pyridyl cyanoguanidine compounds | DAO, CCNY, CBR1 | NAMPT 2731/4885CYP3A4 862/4885CYP2D6 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.